Patients with squamous cell carcinoma of the head and neck (HNSCC) are usually treated by a multimodal approach with surgery and/or radiochemotherapy as the mainstay of local-regional treatment in cases with advanced disease. Both chemotherapy and radiation therapy have the disadvantage of causing severe side effects, while the clinical outcome of patients diagnosed with HNSCC has remained essentially unchanged over the last decade. The potential of immunotherapy is still largely unexplored. Here the authors review the current status of the art and discuss the future challenges in HNSCC treatment and prevention.
|Data di pubblicazione:||2012|
|Titolo:||Immunological treatment options for locoregionally advanced head and neck squamous cell carcinoma.|
|Rivista:||INTERNATIONAL REVIEWS OF IMMUNOLOGY|
|Codice identificativo ISI:||WOS:000299171900003|
|Codice identificativo Scopus:||2-s2.0-84856082393|
|Appare nelle tipologie:||Articolo su Rivista|